Translational Development Acquisition Corp (TDAC) FinancialsTDACTranslational Development Acquisition Corp

Evaluating the bottom line, Translational Development Acquisition Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.44%, provide a clear picture of how effectively TDAC converts its operational activities into shareholder value.

In the context of the broader market, TDAC competes directly with industry leaders such as LIEN and THEO. With a market capitalization of $209.71M, it holds a leading position in the sector. When comparing efficiency, TDAC's gross margin of N/A stands against LIEN's 84.49% and THEO's N/A. Such benchmarking helps identify whether Translational Development Acquisition Corp is trading at a premium or discount relative to its financial performance.

TDAC's recent financial performance shows a net income of $1,662,122 for Q3 2025, demonstrating profitability, although it faced a significant loss in Q4 2025 with a net income of -$553,290. The forward P/E ratio is currently 0, reflecting uncertainty in future earnings.